These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse. Boado RJ; Lu JZ; Hui EK; Pardridge WM Mol Pharm; 2018 Feb; 15(2):602-608. PubMed ID: 29251941 [TBL] [Abstract][Full Text] [Related]
44. IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. Jordan SC; Lorant T; Choi J; Kjellman C; Winstedt L; Bengtsson M; Zhang X; Eich T; Toyoda M; Eriksson BM; Ge S; Peng A; Järnum S; Wood KJ; Lundgren T; Wennberg L; Bäckman L; Larsson E; Villicana R; Kahwaji J; Louie S; Kang A; Haas M; Nast C; Vo A; Tufveson G N Engl J Med; 2017 Aug; 377(5):442-453. PubMed ID: 28767349 [TBL] [Abstract][Full Text] [Related]
45. Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme. Elmore ZC; Oh DK; Simon KE; Fanous MM; Asokan A JCI Insight; 2020 Sep; 5(19):. PubMed ID: 32941184 [TBL] [Abstract][Full Text] [Related]
47. Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumab. Bou-Jaoudeh M; Mimoun A; Delignat S; Peyron I; Capdevila L; Daventure V; Deligne C; Dimitrov JD; Christophe OD; Denis CV; Lenting PJ; Proulle V; Lacroix-Desmazes S J Thromb Haemost; 2023 Oct; 21(10):2776-2783. PubMed ID: 37473843 [TBL] [Abstract][Full Text] [Related]
48. Generating and Purifying Fab Fragments from Human and Mouse IgG Using the Bacterial Enzymes IdeS, SpeB and Kgp. Sjögren J; Andersson L; Mejàre M; Olsson F Methods Mol Biol; 2017; 1535():319-329. PubMed ID: 27914089 [TBL] [Abstract][Full Text] [Related]
49. Slow, continuous enzyme replacement via spinal CSF in dogs with the paediatric-onset neurodegenerative disease, MPS IIIA. King B; Marshall NR; Hassiotis S; Trim PJ; Tucker J; Hattersley K; Snel MF; Jolly RD; Hopwood JJ; Hemsley KM J Inherit Metab Dis; 2017 May; 40(3):443-453. PubMed ID: 27832416 [TBL] [Abstract][Full Text] [Related]
50. Determination of the role of injection site on the efficacy of intra-CSF enzyme replacement therapy in MPS IIIA mice. Beard H; Luck AJ; Hassiotis S; King B; Trim PJ; Snel MF; Hopwood JJ; Hemsley KM Mol Genet Metab; 2015 May; 115(1):33-40. PubMed ID: 25795516 [TBL] [Abstract][Full Text] [Related]
51. Toward Clinical use of the IgG Specific Enzymes IdeS and EndoS against Antibody-Mediated Diseases. Collin M; Björck L Methods Mol Biol; 2017; 1535():339-351. PubMed ID: 27914091 [TBL] [Abstract][Full Text] [Related]
52. AAVrh10 Vector Corrects Disease Pathology in MPS IIIA Mice and Achieves Widespread Distribution of SGSH in Large Animal Brains. Hocquemiller M; Hemsley KM; Douglass ML; Tamang SJ; Neumann D; King BM; Beard H; Trim PJ; Winner LK; Lau AA; Snel MF; Gomila C; Ausseil J; Mei X; Giersch L; Plavsic M; Laufer R Mol Ther Methods Clin Dev; 2020 Jun; 17():174-187. PubMed ID: 31909089 [TBL] [Abstract][Full Text] [Related]
53. IdeS, a highly specific immunoglobulin G (IgG)-cleaving enzyme from Streptococcus pyogenes, is inhibited by specific IgG antibodies generated during infection. Akesson P; Moritz L; Truedsson M; Christensson B; von Pawel-Rammingen U Infect Immun; 2006 Jan; 74(1):497-503. PubMed ID: 16369006 [TBL] [Abstract][Full Text] [Related]
54. Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice. Gliddon BL; Hopwood JJ Pediatr Res; 2004 Jul; 56(1):65-72. PubMed ID: 15128919 [TBL] [Abstract][Full Text] [Related]
55. Fluoxetine ameliorates mucopolysaccharidosis type IIIA. Capuozzo A; Montefusco S; Cacace V; Sofia M; Esposito A; Napolitano G; Nusco E; Polishchuk E; Pizzo MT; De Risi M; De Leonibus E; Sorrentino NC; Medina DL Mol Ther; 2022 Apr; 30(4):1432-1450. PubMed ID: 35121108 [TBL] [Abstract][Full Text] [Related]
56. Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice. Fu H; Kang L; Jennings JS; Moy SS; Perez A; Dirosario J; McCarty DM; Muenzer J Gene Ther; 2007 Jul; 14(14):1065-77. PubMed ID: 17460717 [TBL] [Abstract][Full Text] [Related]
57. IdeS (Imlifidase): A Novel Agent That Cleaves Human IgG and Permits Successful Kidney Transplantation Across High-strength Donor-specific Antibody. Lonze BE; Tatapudi VS; Weldon EP; Min ES; Ali NM; Deterville CL; Gelb BE; Benstein JA; Dagher NN; Wu M; Montgomery RA Ann Surg; 2018 Sep; 268(3):488-496. PubMed ID: 30004918 [TBL] [Abstract][Full Text] [Related]
58. Imlifidase Inhibits HLA Antibody-mediated NK Cell Activation and Antibody-dependent Cell-mediated Cytotoxicity (ADCC) In Vitro. Ge S; Chu M; Choi J; Louie S; Vo A; Jordan SC; Toyoda M Transplantation; 2020 Aug; 104(8):1574-1579. PubMed ID: 32732834 [TBL] [Abstract][Full Text] [Related]
59. Intracerebral injection of sulfamidase delays neuropathology in murine MPS-IIIA. Savas PS; Hemsley KM; Hopwood JJ Mol Genet Metab; 2004 Aug; 82(4):273-85. PubMed ID: 15308125 [TBL] [Abstract][Full Text] [Related]
60. Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA. Roberts AL; Rees MH; Klebe S; Fletcher JM; Byers S Mol Genet Metab; 2007; 92(1-2):115-21. PubMed ID: 17681480 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]